Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 108 of the 109 references it cites were found in a registry or an index; 32 of the 99 sources its claims cite were checked for support.

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific

Open access

Abstract

Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations. Although epidemiological studies connect specific alleles to clinical outcomes, the mechanisms underlying the distinct clinical characteristics of mutant KRAS alleles are unclear. Here, we analyze 13,492 samples from these four tumor types to examine allele- and tissue-specific genetic properties associated with oncogenic KRAS mutations. The prevalence of known mutagenic mechanisms partially explains the observed spectrum of KRAS activating mutations. However, there are substantial differences between the observed and predicted frequencies for many alleles, suggesting that biological selection underlies the tissue-specific frequencies of mutant alleles. Consistent with experimental studies that have identified distinct signaling properties associated with each mutant form of KRAS, our genetic analysis reveals that each KRAS allele is associated with a distinct tissue-specific comutation network. Moreover, we identify tissue-specific genetic dependencies associated with specific mutant KRAS alleles. Overall, this analysis demonstrates that the genetic interactions of oncogenic KRAS mutations are allele- and tissue-specific, underscoring the complexity that drives their clinical consequences.

Overview

CoChat Summary

TL;DR

This study analyzes 13,492 COAD, LUAD, MM, and PAAD samples to show that oncogenic KRAS allele frequencies are shaped partly by tissue-specific mutational processes but also by biological selection. It finds that each KRAS allele has distinct tissue-specific comutation networks and genetic dependencies, with some dependencies explained by comutating partner genes.

Key findings

  • KRAS mutation prevalence varied by cancer: PAAD 86%, COAD 41%, LUAD 35%, and MM 22%. Across hotspots, codon 12 accounted for 72.2% of mutations, codon 13 for 9.8%, codon 61 for 14.8%, and codon 146 for 3.2%; incidence-adjusted distribution was 76.8%, 11.4%, 8.1%, and 3.7%, respectively.
  • Mutational signatures only partially explained allele frequencies. Examples: COAD G13D was predicted at 27% but observed at 20%; MM Q61H was predicted at 15.0% but observed at 35.7%; PAAD G12R was expected at 5.2% but observed at 16.7%. Pearson correlations between observed and predicted frequencies were 0.4–0.6 overall and 0.7–0.9 when restricted to G12 alleles.
  • Each KRAS allele had a distinct tissue-specific comutation network. In MM, NRAS had reduced comutation with KRAS G12D, Q61L, and Q61R, but 18.5% comutation with Q61H, just below the 23.6% NRAS mutation rate in KRAS WT tumors. In COAD, TP53 comutation was reduced with KRAS G12D and G13D.
  • Allele-specific genetic dependencies were identified in cell lines: 62 genes in COAD and 130 genes in PAAD. Examples include stronger LIN7C dependency in KRAS G13D COAD lines, greater TFPT dependency in G12D lines, and reduced STARD9 dependency in G12D lines. Integrated models showed some dependencies could be attributed to comutation partners, such as STARD9 with TP53 and EEF1E1, ABI1, and MYBL2 with SMAD4.

Methods

  • Public WGS, WES, and targeted-sequencing data were collected for COAD, LUAD, MM, and PAAD from cBioPortal, ICGC, MMRF-CoMMpass, and AACR GENIE v5, totaling 13,492 samples. Hypermutated COAD samples were identified with a Gaussian mixed model and excluded from comutation analysis.
  • Mutational signatures were discovered with SigProfiler NMF and quantified by nonnegative least squares. Predicted KRAS allele frequencies were calculated from same-trinucleotide-context mutation frequencies genome-wide and compared with observed frequencies using χ-squared tests with Benjamini–Hochberg FDR. Comutation was tested with one-sided Fisher’s exact tests for increased comutation and the Leiserson row-column exclusivity test for reduced comutation.
  • Genetic dependencies were analyzed using DepMap 2020Q1 CERES CRISPR scores, restricted to KRAS alleles present in at least three cell lines. Differential dependency was tested by ANOVA (p < 0.01) and t tests (FDR-adjusted p < 0.05), with GSEA and elastic net linear models incorporating comutation covariates and RNA expression.

Limitations

  • The paper states that MM comutation analysis was hampered by frequent multiclonality, so it was limited to genes known to be recurrently mutated in MM to reduce false positives. It also notes that reduced-comutation analysis required WGS/WES data and could not use targeted-sequencing data.
  • The paper states that hypermutated COAD samples were excluded from comutation analysis because passenger mutations would add noise, and that genetic dependency analysis was restricted to COAD and PAAD cell lines and to KRAS alleles with at least three cell lines; PAAD lacked enough WT KRAS cell lines for inclusion.
  • Evident from the text: comutation and dependency analyses are observational and correlational, and the authors note that some allele-specific dependency signals could instead be attributed to comutating partner genes. The cell-line dependency models also had limited numbers of cell lines relative to covariates and used elastic net regularization.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-021-22125-z

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The contribution of mutational processes to KRAS mutagenesis. a The frequency of KRAS mutations in each cancer. b The distribution of KRAS allele frequencies at the four hotspots, codons 12 (left), 13 (middle-left), 61 (middle-right), and 146 (right) in each cancer. The size of the circle reflects the percent of KRAS mutations that are the indicated allele in each cancer. Each cancer is assigned a different color. The number of tumor samples whose sequencing data was collected for this study is indicated along the y-axis. c The average composition of mutational signatures in tumor samples grouped by KRAS allele. Each color represents a different mutational signature. Mutational signatures of know etiology are annotated. d The average probability of each mutational signature to have caused the KRAS mutation in a tumor sample. This value accounts for the level of each mutational signature in the tumor sample, and the ability of the mutational signature to cause the indicated KRAS allele. In c and d, only KRAS alleles found in at least 15 tumor samples of the cancer type are included. Source data are provided in the Source data file.
Fig. 1 The contribution of mutational processes to KRAS mutagenesis. a The frequency of KRAS mutations in each cancer. b The distribution of KRAS allele frequencies at the four hotspots, codons 12 (left), 13 (middle-left), 61 (middle-right), and 146 (right) in each cancer. The size of the circle reflects the percent of KRAS mutations that are the indicated allele in each cancer. Each cancer is assigned a different color. The number of tumor samples whose sequencing data was collected for this study is indicated along the y-axis. c The average composition of mutational signatures in tumor samples grouped by KRAS allele. Each color represents a different mutational signature. Mutational signatures of know etiology are annotated. d The average probability of each mutational signature to have caused the KRAS mutation in a tumor sample. This value accounts for the level of each mutational signature in the tumor sample, and the ability of the mutational signature to cause the indicated KRAS allele. In c and d, only KRAS alleles found in at least 15 tumor samples of the cancer type are included. Source data are provided in the Source data file.CC BY · PubMed Central
Fig. 2 The predicted frequencies of cancer-specific KRAS alleles. a The predicted versus observed frequency of KRAS alleles for the common alleles of each cancer. Triangles indicate rejection of the null hypothesis that the observed and predicted frequencies are the same (χ-squared test, p values were adjusted using the Benjamini–Hochberg FDR correction method, hereon referred to as FDR-adjusted p values; FDR-adjusted p value < 0.05); circles indicate the failure to reject the null hypothesis (χ-squared test, FDR-adjusted p value ≥ 0.05). Error bars indicate bootstrapped 95% confidence intervals of the predicted values. b The average probability of the indicated KRAS allele in tumors samples with the KRAS allele (closed circle), tumors samples with a different KRAS mutation (open circle), and tumor samples with WT KRAS (upside-down triangle). The errors bars indicate bootstrapped 95% confidence intervals of the mean. For each allele, differences in the probabilities between tumor samples with the allele and those with another allele, and between tumor samples with the allele and those with WT KRAS were tested via a Wilcoxon rank-sum test (FDR-adjusted p values < 0.05 are indicated). Source data are provided in the Source data file.
Fig. 2 The predicted frequencies of cancer-specific KRAS alleles. a The predicted versus observed frequency of KRAS alleles for the common alleles of each cancer. Triangles indicate rejection of the null hypothesis that the observed and predicted frequencies are the same (χ-squared test, p values were adjusted using the Benjamini–Hochberg FDR correction method, hereon referred to as FDR-adjusted p values; FDR-adjusted p value < 0.05); circles indicate the failure to reject the null hypothesis (χ-squared test, FDR-adjusted p value ≥ 0.05). Error bars indicate bootstrapped 95% confidence intervals of the predicted values. b The average probability of the indicated KRAS allele in tumors samples with the KRAS allele (closed circle), tumors samples with a different KRAS mutation (open circle), and tumor samples with WT KRAS (upside-down triangle). The errors bars indicate bootstrapped 95% confidence intervals of the mean. For each allele, differences in the probabilities between tumor samples with the allele and those with another allele, and between tumor samples with the allele and those with WT KRAS were tested via a Wilcoxon rank-sum test (FDR-adjusted p values < 0.05 are indicated). Source data are provided in the Source data file.CC BY · PubMed Central
Fig. 3 The comutation networks of oncogenic KRAS alleles. a The comutation network of the KRAS alleles in COAD with each edge representing a significant comutation interaction between an allele and another gene (p value < 0.01). The color of the edge indicates whether the interaction was an increase (blue) or decrease (green) in the frequency of comutation. Genes with multiple interactions are represented by a gray dot to disambiguate them from where edges intersect. b A subset of the network shown in a of genes that encode proteins known to physically interact with KRAS, are in one of its canonical upstream or downstream pathways, or are validated oncogenes or tumor suppressors. The width of the edge indicates the strength of the association. c Cellular functions enriched in the comutation networks of the KRAS alleles in COAD (left), LUAD (center), and PAAD (right). The size of the dot indicates the number of genes in both the function and the comutation network, and the transparency indicates the FDR-adjusted p value of the enrichment. d, e A visualization of the increased (d) or decreased (e) comutation of select genes with KRAS G12D in COAD. Rows of the central plot represent genes. Each column of the central plot is a different tumor sample. A filled space denotes a mutation of the gene in the sample, the color describing the type of variant. The bar plots above and to the right indicate the marginal values of the central plot. f A comparison of the comutation frequencies in PAAD of the genes producing proteins in the PPIN of SMAD1-3. Each column is a gene with a comutation interaction with a KRAS allele and in at least one of the gene sets. The black tiles on top indicate that the gene was in the PPIN of the indicated SMAD protein. The bar plot shows the distribution of the comutation events of each gene across tumor samples with the various KRAS mutations. n = 4145 COAD, 5051 LUAD, 1262 MM, and 2314 PAAD biologically independent tumor samples for the increased comutation analysis, and n = 1536 COAD, 891 LUAD, 1395 PAAD biologically independent tumor samples for the reduced comutation analysis. Source data are provided in the Source data file.
Fig. 3 The comutation networks of oncogenic KRAS alleles. a The comutation network of the KRAS alleles in COAD with each edge representing a significant comutation interaction between an allele and another gene (p value < 0.01). The color of the edge indicates whether the interaction was an increase (blue) or decrease (green) in the frequency of comutation. Genes with multiple interactions are represented by a gray dot to disambiguate them from where edges intersect. b A subset of the network shown in a of genes that encode proteins known to physically interact with KRAS, are in one of its canonical upstream or downstream pathways, or are validated oncogenes or tumor suppressors. The width of the edge indicates the strength of the association. c Cellular functions enriched in the comutation networks of the KRAS alleles in COAD (left), LUAD (center), and PAAD (right). The size of the dot indicates the number of genes in both the function and the comutation network, and the transparency indicates the FDR-adjusted p value of the enrichment. d, e A visualization of the increased (d) or decreased (e) comutation of select genes with KRAS G12D in COAD. Rows of the central plot represent genes. Each column of the central plot is a different tumor sample. A filled space denotes a mutation of the gene in the sample, the color describing the type of variant. The bar plots above and to the right indicate the marginal values of the central plot. f A comparison of the comutation frequencies in PAAD of the genes producing proteins in the PPIN of SMAD1-3. Each column is a gene with a comutation interaction with a KRAS allele and in at least one of the gene sets. The black tiles on top indicate that the gene was in the PPIN of the indicated SMAD protein. The bar plot shows the distribution of the comutation events of each gene across tumor samples with the various KRAS mutations. n = 4145 COAD, 5051 LUAD, 1262 MM, and 2314 PAAD biologically independent tumor samples for the increased comutation analysis, and n = 1536 COAD, 891 LUAD, 1395 PAAD biologically independent tumor samples for the reduced comutation analysis. Source data are provided in the Source data file.CC BY · PubMed Central
Fig. 4 Allele-specific genetic dependencies in COAD cell lines. a Gene sets with significant enrichment for increased (lower dependency score; purple) or reduced (higher dependency score; orange) genetic dependency in COAD cell lines. The size of the dot relates the FDR-adjusted p value of the association and the color indicates the strength of the enrichment (“normalized enrichment score”). b, c Heatmaps ranking the cell lines by dependency (“dep.”) score of the genes at the leading edge of enrichment for two gene sets. Each row represents a gene and each cell represents a cell line colored by its KRAS allele. The cell lines are arranged in ranking order by their dependency score for the gene. Thus, each column indicates a rank. The line plots above the heatmaps indicate the representation (density) of each KRAS allele at each rank across the genes. d Hierarchically clustered heatmaps of the genes that demonstrated differential genetic dependency amongst cell lines of different KRAS alleles. Each column is a cell line labeled by its DepMap identifier and each row is a gene. e Examples of genes that demonstrated differential genetic dependency amongst cell lines of different KRAS alleles (t tests; FDR-adjusted p values). For the box plots, the box demarcations represent the 25th, 50th, and 75th percentiles, and the whiskers extend from the box to the largest and smallest data points at most 1.5 times the interquartile range away from the median. n = 23 biologically independent COAD cell lines. Source data are provided in the Source data file.
Fig. 4 Allele-specific genetic dependencies in COAD cell lines. a Gene sets with significant enrichment for increased (lower dependency score; purple) or reduced (higher dependency score; orange) genetic dependency in COAD cell lines. The size of the dot relates the FDR-adjusted p value of the association and the color indicates the strength of the enrichment (“normalized enrichment score”). b, c Heatmaps ranking the cell lines by dependency (“dep.”) score of the genes at the leading edge of enrichment for two gene sets. Each row represents a gene and each cell represents a cell line colored by its KRAS allele. The cell lines are arranged in ranking order by their dependency score for the gene. Thus, each column indicates a rank. The line plots above the heatmaps indicate the representation (density) of each KRAS allele at each rank across the genes. d Hierarchically clustered heatmaps of the genes that demonstrated differential genetic dependency amongst cell lines of different KRAS alleles. Each column is a cell line labeled by its DepMap identifier and each row is a gene. e Examples of genes that demonstrated differential genetic dependency amongst cell lines of different KRAS alleles (t tests; FDR-adjusted p values). For the box plots, the box demarcations represent the 25th, 50th, and 75th percentiles, and the whiskers extend from the box to the largest and smallest data points at most 1.5 times the interquartile range away from the median. n = 23 biologically independent COAD cell lines. Source data are provided in the Source data file.CC BY · PubMed Central
Fig. 5 Some dependency interactions can be explained by comutation events. a The nonzero coefficients for the model of STARD9 dependency in COAD cell lines regressed on KRAS G12D (versus all other KRAS alleles) and its comutation interactors (top), and the actual dependency scores for KRAS G12D mutant and TP53-mutant cell lines (bottom). Cell lines without either mutation or with both are not shown. KRAS G12D has reduced comutation with TP53 in COAD. b–d The nonzero coefficients for the models of b EEF1E1, c ABL1, and d MYBL2 dependency in PAAD cell lines regressed on KRAS G12D (versus all other KRAS alleles) and its comutation interactors (top), and the actual dependency scores for KRAS G12D mutant and SMAD4 mutant cell lines (bottom). Cell lines without either mutation or with both are not shown. KRAS G12D has reduced comutation with SMAD4 in PAAD. For the box plots, the box demarcations represent the 25th, 50th, and 75th percentiles, and the whiskers extend from the box to the largest and smallest data points at most 1.5 times the interquartile range away from the median. n = 23 biologically independent COAD cell lines, and n = 23 biologically independent PAAD cell lines. Source data are provided in the Source data file.
Fig. 5 Some dependency interactions can be explained by comutation events. a The nonzero coefficients for the model of STARD9 dependency in COAD cell lines regressed on KRAS G12D (versus all other KRAS alleles) and its comutation interactors (top), and the actual dependency scores for KRAS G12D mutant and TP53-mutant cell lines (bottom). Cell lines without either mutation or with both are not shown. KRAS G12D has reduced comutation with TP53 in COAD. b–d The nonzero coefficients for the models of b EEF1E1, c ABL1, and d MYBL2 dependency in PAAD cell lines regressed on KRAS G12D (versus all other KRAS alleles) and its comutation interactors (top), and the actual dependency scores for KRAS G12D mutant and SMAD4 mutant cell lines (bottom). Cell lines without either mutation or with both are not shown. KRAS G12D has reduced comutation with SMAD4 in PAAD. For the box plots, the box demarcations represent the 25th, 50th, and 75th percentiles, and the whiskers extend from the box to the largest and smallest data points at most 1.5 times the interquartile range away from the median. n = 23 biologically independent COAD cell lines, and n = 23 biologically independent PAAD cell lines. Source data are provided in the Source data file.CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 0 Not valid · 28 Not checked · 125 Own results and interpretations

110 more claims · 2 with their cited sources checked

Create a free account to see all 168 claims and to verify the 67 references still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 34

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 109 references

Cited by

See all 209

Metadata

Authors
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M.
Affiliations
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • Broad Institute (US)
Corresponding author
  • Park, Peter J.
  • Haigis, Kevin M.
Venue
Nature Communications
Published
2021-03-22
Volume
12
Issue
1
Pages
1808-1808
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3138323180
Cited by
208
References
109
Citations by year
2026: 30 · 2025: 45 · 2024: 48 · 2023: 39 · 2022: 35 · 2021: 11
FWCI
13.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Association for Cancer Research
  • Multiple Myeloma Research Foundation
  • Cancer Research UK (27144)
  • National Institutes of Health
  • National Cancer Institute (R01CA232372, U01CA199252)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
KRAS mutation, colorectal cancer, pancreatic cancer, lung cancer, missense mutations, gene dependency, mutagenic mechanisms
MeSH terms
Alleles, Gene Frequency, Humans, Mutation, Neoplasms, Organ Specificity, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Gene Regulatory Networks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. https://app.cochat.ai/papers/10.1038/s41467-021-22125-z
The paper
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021). The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nature Communications. https://doi.org/10.1038/s41467-021-22125-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.